Business Segments · Subtotal
North American Pharmaceutical — Subtotal
McKesson North American Pharmaceutical — Subtotal remained flat by 0.0% to $914.5M in Q4 2026 compared to the prior quarter. Year-over-year, this metric declined by 13.3%, from $1.06B to $914.5M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityStable
First reportedQ3 2024
Last reportedQ4 2026May 8, 2026
How to read this metric
Changes in this subtotal reflect shifts in the underlying profitability drivers before final corporate allocations or tax considerations.
Detailed definition
This metric represents an intermediate financial subtotal for the North American Pharmaceutical segment, typically used...
Peer comparison
Commonly used in segment reporting to provide transparency into the build-up of operating profit, consistent with GAAP segment disclosure requirements.
Metric ID:
mck_segment_north_american_pharmaceutical_subtotalHistorical Data
8 periods
| Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $347M | $744M | $852M | $1.06B | $914.5M | $914.5M | $914.5M | $914.5M |
| QoQ Change | — | +114.4% | +14.5% | +23.8% | -13.3% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | +145.5% | +41.8% | — | — | +7.3% | -13.3% |
Range$347M – $1.06B
CAGR+74.0%
Avg YoY Growth+45.3%
Median YoY Growth+24.6%
Current Streak3 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's north american pharmaceutical — subtotal?
- McKesson (MCK) reported north american pharmaceutical — subtotal of $914.5M in Q4 2026.
- How has McKesson's north american pharmaceutical — subtotal changed year-over-year?
- McKesson's north american pharmaceutical — subtotal decreased by 13.3% year-over-year, from $1.06B to $914.5M.
- What does north american pharmaceutical — subtotal mean?
- An intermediate financial subtotal used to reconcile the North American Pharmaceutical segment's performance.